

Test Report

Ordered By

Fran Lake, PhD, MD.

Collection Date

03/07/2023

Specimen ID

665544

Patient Information

Name Jane Lee Sex

F

Date of Birth

Medical Record Number

01/01/1960 00998877

kidneyintelX.dkd LEVEL



In the clinical performance study*, approximately 5% (95% CI 3% to 7%) of patients with Low kidneyintelX.dkd Levels experienced progressive decline in kidney function within 5 years after their test result.

Signed

Michael Smith PhD, MD.

Laboratory Director: Michael Smith PhD, MD.

CLIA Number: 112233445566

Renalytix, 101 6th Avenue, 3rd Floor, Room 324, New York, NY 10013

Report Date

Time

03/14/2023

10:05 AM (UTC)

kidneyintelX.dkd Level	Percent of Patients Experiencing Progressive Decline in Kidney Function (95% CI)	Percent of Patients Experiencing End Stage Kidney Disease (95% CI)
Low	4.6% (2.7% – 7.2%)	0.0%
Moderate	16.7% (12.1% – 22.2%)	3.1% (1.2% – 6.2%)
High	41.8% (28.7% – 55.9%)	18.2% (9.1% – 30.9%)

*Based on clinical performance study results in the kidneyintelX.dkd Product Technical Sheet. The kidneyintelX.dkd Levels (Low, Moderate, and High) correlate with the probability of progressive decline in kidney function.

To receive a kidneyintelX.dkd Product Technical Sheet, contact Client Services at (888) 203-2725 or at clientservices@renalytix.com.

kidneyintelX.com



renalytix™

kidneyintelX.dkd Product Technical Sheet (printed copy) is promptly provided at no cost upon request.